These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37149931)

  • 1. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents.
    Ertesvåg NU; Iversen A; Blomberg B; Özgümüş T; Rijal P; Fjelltveit EB; Cox RJ; Langeland N;
    EBioMedicine; 2023 Jun; 92():104599. PubMed ID: 37149931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway.
    Iversen A; Blomberg B; Haug K; Kittang B; Özgümüs T; Cox RJ; Langeland N
    Front Public Health; 2024; 12():1320059. PubMed ID: 38504678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Event rates and incidence of post-COVID-19 condition in hospitalised SARS-CoV-2 positive children and young people and controls across different pandemic waves: exposure-stratified prospective cohort study in Moscow (StopCOVID).
    Pazukhina E; Rumyantsev M; Baimukhambetova D; Bondarenko E; Markina N; El-Taravi Y; Petrova P; Ezhova A; Andreeva M; Iakovleva E; Bobkova P; Pikuza M; Trefilova A; Abdeeva E; Galiautdinova A; Filippova Y; Bairashevskaia A; Zolotarev A; Bulanov N; DunnGalvin A; Chernyavskaya A; Kondrikova E; Kolotilina A; Gadetskaya S; Ivanova YV; Turina I; Eremeeva A; Fedorova LA; Comberiati P; Peroni DG; Nekliudov N; Genuneit J; Reyes LF; Brackel CLH; Mazankova L; Miroshina A; Samitova E; Borzakova S; Carson G; Sigfrid L; Scott JT; McFarland S; Greenhawt M; Buonsenso D; Semple MG; Warner JO; Olliaro P; Osmanov IM; Korsunskiy AA; Munblit D;
    BMC Med; 2024 Feb; 22(1):48. PubMed ID: 38302974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: An observational cohort study.
    Seery V; Raiden S; Russo C; Borda M; Herrera L; Uranga M; Varese A; Marcó Del Pont M; Chirino C; Erramuspe C; Álvarez LS; Lenoir M; Morales LD; Davenport C; Alarcón Flores A; Huespe Auchter S; Ruiz Y; Monsalvo L; Sastoque L; Gavazzi M; Mazzitelli I; Di Diego F; Longueira Y; Mazzitelli B; Sananez I; De Carli N; Biglione MM; Gómez Penedo JM; Ceballos A; Laufer N; Ferrero F; Geffner J; Arruvito L
    EBioMedicine; 2022 Sep; 83():104230. PubMed ID: 35988465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Symptoms Associated With SARS-CoV-2 Variants Among Children in Canada.
    Sumner MW; Xie J; Zemek R; Winston K; Freire G; Burstein B; Kam A; Emsley J; Gravel J; Porter R; Sabhaney V; Mater A; Salvadori MI; Berthelot S; Beer D; Poonai N; Moffatt A; Wright B; Freedman SB;
    JAMA Netw Open; 2023 Mar; 6(3):e232328. PubMed ID: 36892839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
    Stich M; Benning L; Speer C; Garbade SF; Bartenschlager M; Kim H; Jeltsch K; Tabatabai J; Niesert M; Janda A; Renk H; Elling R; Hoffmann GF; Kräusslich HG; Müller B; Bartenschlager R; Tönshoff B
    J Med Virol; 2023 Mar; 95(3):e28582. PubMed ID: 36794653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of post-COVID symptoms of the SARS-CoV-2 Delta and Omicron variants in children: a prospective study.
    Yildirim Arslan S; Avcu G; Sahbudak Bal Z; Arslan A; Ozkinay FF; Kurugol Z
    Eur J Pediatr; 2023 Oct; 182(10):4565-4571. PubMed ID: 37526704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study.
    Gottlieb M; Wang RC; Yu H; Spatz ES; Montoy JCC; Rodriguez RM; Chang AM; Elmore JG; Hannikainen PA; Hill M; Huebinger RM; Idris AH; Lin Z; Koo K; McDonald S; O'Laughlin KN; Plumb ID; Santangelo M; Saydah S; Willis M; Wisk LE; Venkatesh A; Stephens KA; Weinstein RA;
    Clin Infect Dis; 2023 Jun; 76(11):1930-1941. PubMed ID: 36705268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
    Jeffery-Smith A; Rowland TAJ; Patel M; Whitaker H; Iyanger N; Williams SV; Giddings R; Thompson L; Zavala M; Aiano F; Ellis J; Lackenby A; Höschler K; Brown K; Ramsay ME; Gopal R; Chow JY; Ladhani SN; Zambon M
    Lancet Healthy Longev; 2021 Dec; 2(12):e811-e819. PubMed ID: 34873592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study.
    Zhang H; Huang C; Gu X; Wang Y; Li X; Liu M; Wang Q; Xu J; Wang Y; Dai H; Zhang D; Cao B
    Lancet Respir Med; 2024 Jan; 12(1):55-66. PubMed ID: 38000376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
    de Bruijn S; van Hoek AJ; Mutubuki EN; Knoop H; Slootweg J; Tulen AD; Franz E; van den Wijngaard CC; van der Maaden T
    Heliyon; 2024 Apr; 10(7):e28941. PubMed ID: 38617937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022.
    Veneti L; Berild JD; Watle SV; Starrfelt J; Greve-Isdahl M; Langlete P; Bøås H; Bragstad K; Hungnes O; Meijerink H
    Int J Infect Dis; 2023 May; 130():182-188. PubMed ID: 36893942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection-Final Update of a Living, Rapid Review.
    Holmer HK; Mackey K; Fiordalisi CV; Helfand M
    Ann Intern Med; 2023 Jan; 176(1):85-91. PubMed ID: 36442059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: a comparative study in western Mexico.
    Peña Rodríguez M; Hernández Bello J; Vega Magaña N; Viera Segura O; García Chagollán M; Ceja Gálvez HR; Mora Mora JC; Rentería Flores FI; García González OP; Muñoz Valle JF
    Front Public Health; 2023; 11():1149795. PubMed ID: 37181688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.